Related Experiment Videos
Huntington's disease: changes in tachykinin content in postmortem brains
H Arai1, P C Emson, L H Carrasco
1Department of Neuroendocrinology, AFRC Institute of Animal Physiology and Genetics Research, Babraham, Cambridge, UK.
Annals of Neurology
|November 1, 1987
Summary
Huntington's disease brains show reduced levels of key neuropeptides, including Substance P and neurokinin A, particularly in the substantia nigra. This depletion correlates with observed cell loss in the striatum, suggesting a link between these neurochemical changes and disease progression.
Area of Science:
- Neuroscience
- Neuropathology
- Molecular Biology
Background:
- Huntington's disease (HD) is a neurodegenerative disorder.
- Tachykinins, a class of neuropeptides, play roles in neuronal function.
- Alterations in neuropeptide levels may contribute to HD pathogenesis.
Purpose of the Study:
- To quantify levels of specific tachykinins in post-mortem brains from Huntington's disease patients and controls.
- To investigate the correlation between tachykinin depletion and neuropathological changes in HD.
Main Methods:
- Post-mortem brain tissue analysis from Huntington's disease and control subjects.
- Measurement of Substance P, neurokinin A, neuropeptide K, and neurokinin B concentrations.
- Immunocytochemistry techniques to assess peptide co-localization and depletion.
Main Results:
- Significant reductions in all four measured tachykinins were found in the substantia nigra of Huntington's disease brains.
- Neuropeptide K was also significantly reduced in the frontal cortex of HD cases.
- Tachykinin depletion in the substantia nigra strongly correlated with striatal cell loss in Huntington's disease.
Conclusions:
- Huntington's disease is characterized by widespread tachykinin depletion, especially in the substantia nigra.
- These neurochemical deficits are linked to the degree of neurodegeneration observed in the striatum.
- Substance P and neurokinin A coexist in the substantia nigra, and their immunoreactivity is markedly reduced in Huntington's disease.